- Home
- PLTR vs NVO Comparison
PLTR vs NVO Comparison
Compare PLTR & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLTR | NVO |
|---|---|---|
| Founded | 2003 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9B | 197.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLTR | NVO |
|---|---|---|
| Price | $130.74 | $43.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 11 |
| Target Price | ★ $192.83 | $51.00 |
| AVG Volume (30 Days) | ★ 32.2M | 11.0M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | ★ 231.58 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $4,475,446,000.00 | N/A |
| Revenue This Year | $65.66 | N/A |
| Revenue Next Year | $42.35 | $3.70 |
| P/E Ratio | $392.38 | ★ $13.60 |
| Revenue Growth | ★ 56.18 | N/A |
| 52 Week Low | $122.68 | $35.12 |
| 52 Week High | $207.46 | $71.80 |
Technical Indicators
Market Signals| Indicator | PLTR | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 50.81 |
| Support Level | $127.13 | $43.35 |
| Resistance Level | $152.85 | $50.30 |
| Average True Range (ATR) | 6.82 | 1.32 |
| MACD | -0.99 | -0.06 |
| Stochastic Oscillator | 10.85 | 53.87 |
Price Performance
Historical ComparisonAbout PLTR Palantir Technologies Inc.
Palantir is an artificial intelligence, analytics, and automated decision-making company that leverages data to drive efficiency across its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The company was founded in 2003 and went public in 2020.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.